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Abstract
Objectives. To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in
SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to
anti-dsDNA antibody levels.
Methods. Sixty-one patients with refractory SLE were treated with a standard rituximab regimen. Clinical
and serological measures of disease activity and B-cell numbers were assessed. B-cell phenotype was
examined in a subgroup of patients by flow cytometry.
Results. Disease relapse was substantially delayed beyond B-cell repopulation, and early relapse was
associated with a faster rate of repopulation. At relapse, B-cell numbers were significantly lower than at
baseline in patients with high anti-dsDNA antibody levels (>100IU/ml) but not in patients with low
anti-dsDNA antibody levels. Of the patients with high anti-dsDNA antibodies at baseline, levels fell sig-
nificantly only in those patients who remained in remission after repopulation. Relapse with high
anti-dsDNA antibody levels was associated with an increased percentage of IgD
CD27
hi plasmablasts,
whereas relapse with low anti-dsDNA antibody levels was accompanied by an increased percentage of
IgD
CD27
 B cells.
Conclusion. Anti-dsDNA antibody levels distinguished two patient groups, which differ in their B-cell
number and phenotype at relapse following rituximab, and suggest that different B-cell pathologies
exist in SLE. The data imply that B-cell numbers should be kept very low for a sustained period in patients
with high dsDNA binding, therefore justifying a more aggressive regimen.
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Introduction
SLE is an autoimmune rheumatic disease with heteroge-
neous clinical manifestations typically characterized by
B-cell activation and autoantibodies that target nuclear
antigens [1]. In addition to the multiple abnormalities in
B cells found in patients with SLE and animal models of
the disease, the importance of B cells in this disease has
been reinforced by many reports describing clinical and
serological improvements in patients with SLE that have
been treated with the B-cell-depleting agent rituximab
[24]. In our cohort, >80% of patients with SLE refractory
to conventional therapy responded to their first cycle of
rituximab [2]. Surprisingly, randomized control trials have
failed to confirm the efficacy of rituximab in SLE [5].
The heterogeneous nature of SLE suggests that the
pathogenesis varies between individual patients, which
could modify the response to rituximab. The identification
and utilization of biomarkers, which may reflect alternate
disease mechanisms, could identify which patients are
more likely to respond as well as aid in the design of
more effective therapies. Anti-dsDNA antibodies are
recognized as highly specific diagnostic markers for SLE
and human monoclonal anti-dsDNA antibodies have been
shown to be pathogenic in recipient immunodeficient
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Emice [6]. Anti-dsDNA antibodies are routinely measured to
monitor disease activity in SLE, and increases in their titre
have been used as a guide to treat lupus patients with
conventional therapy before flares are clinically apparent
[7, 8]. Moreover, a decrease in anti-dsDNA antibody titres
has been associated with a clinical response to rituximab
[2, 9]. Approximately 30% of patients with lupus do not
have raised levels of anti-dsDNA antibodies, and whether
these patients respond differently to rituximab remains
unclear.
B-cell homeostasis is significantly disturbed in patients
with SLE, which includes an increased population of plas-
mablasts and double negative (IgD
CD27
) B cells [10].
B-cell depletion leads to a profound reduction in all these
subsets, with long-term responders appearing to have a
relatively immature B-cell compartment following B-cell
repopulation [11]. In general, rituximab tends to restore
B-cell homeostasis in lupus, although there is consider-
able variation between individual patients [12]. Indeed, the
kinetics of B-cell repopulation in individual lupus patients
receiving rituximab and its relationship with disease
relapse has not been fully elucidated. We investigated
whether these factors could be integrated to understand
divergent treatment responses and relate these findings to
the timing of disease relapse following rituximab.
Patients and methods
Patients with SLE (all of whom met the revised classifica-
tion criteria for the disease [13]) were treated on the basis
that they had failed to respond to standard immunosup-
pressive therapy [prednisolone and at least one of the
following, percentage of patients in brackets: AZA (70%),
CYC (42%) and mycophenolate (26%)]. All had active dis-
easeasdefinedbytheclassicBILAGindex,scoringatleast
one A or two Bs in one of eight organ-based systems [14].
The treatment regimen included two infusions of i.v. ritux-
imab (1000mg) 14 days apart with i.v. methylprednisolone
(100250mg) and i.v. CYC (750mg), in all but two patients,
the day after the first rituximab infusion.
Clinical assessment including disease relapse was
determined by an increase in the clinical indices of
active disease, based on the classic BILAG index [14].
Patients attended on average every 2 months. Disease
activity was graded in eight organ-based systems from
an A grade (highest disease activity) to E, the lowest.
Patients were deemed to have relapsed if they had one
new A grade or two new B grades after rituximab therapy.
Anti-dsDNA antibody levels were measured by ELISA
(Shield Diagnostics Dundee, UK) (normal <50 U/ml). This
study was approved by the University College London
Hospitals (UCLH) Ethics Committee and all patients
gave written informed consent according to the
Declaration of Helsinki. Patient numbers are indicated
for each part of the study.
B-cell quantification
B cells were counted in the haematology laboratory of
UCLH from 4ml of blood collected in tubes containing
EDTA. PBMCs were extracted and labelled with CD19
antibodies. The CD19
+ B cells were then measured on a
flow cytometer.
Cell separation and flow cytometry
For a subset of patients, PBMCs were extracted using
lymphoprep and stained using antibodies for the
markers CD19 (APC/PE-Cy7, eBioscience), IgD (FITC,
BD Biosciences) and CD27 (PE, BD Biosciences). The
levels of expression of these markers were recorded by
FACS. The data were analysed using FlowJo software.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 4 Version 4.0c software. Wilcoxon signed-rank
test was used to compare paired data before and after
rituximab therapy. MannWhitney test was used to com-
pare unpaired data between groups. KaplanMeier curves
were generated to compare time to B-cell repopulation.
Log rank test was used to examine differences between
the curves. Analysis of correlation was done using linear
regression. Fisher’s exact test was used to determine the
association of renal disease and raised anti-dsDNA anti-
body levels.
Results
Patients—summary of baseline characteristics
The median age at diagnosis of the patients studied was
23 years (range 1066 years) and at treatment was
33 years (range 1773 years). Disease duration prior
to B-cell depletion therapy (BCDT) ranged from 0 to
28 years (median 6.5 years). Of the patients treated, 56
were females and 5 were males. Supplementary Table 1
(available as supplementary data at Rheumatology Online)
describes the active organ involvement at time of treat-
ment, indication for treatment, age and duration of dis-
ease at BCDT, and ethnic origin of the patients. There
was a significant association between renal disease and
elevated anti-dsDNA antibodies (>100IU/l) in our patient
cohort; 20 of 26 patients with high anti-dsDNA antibodies
had nephritis compared with 11 of 35 patients who had
low or normal anti-dsDNA antibody levels (P<0.0007).
A more rapid rate of B-cell repopulation in patients
who relapse earlier
The median B-cell number before treatment was
0.12210
9/l (range 0.0100.67910
9/l). Following ritux-
imab therapy all patients achieved B-cell depletion,
defined as a B-cell count of <0.0110
9/l. The median
time to repopulation (defined as a B-cell count of
>0.0110
9 B cells/l) following rituximab therapy was
32 weeks and to clinical relapse (defined as a new
BILAG A score or two new Bs) was 66 weeks. The rate
of repopulation was greater than the rate of relapse
(P<0.001) (Fig. 1A).
To examine whether early repopulation was associated
with early relapse, patients were divided into three groups
according to whether they repopulated before 16 weeks
(n=10), between weeks 16 and 32 (n=22), or after
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early repopulation was associated with early relapse
(P<0.001) (Fig. 1B). Furthermore, 39 and 45% of patients
had inactive disease for >2 years in the group of patients
that repopulated between 16 and 32 weeks, and after 32
weeks, respectively, compared with only 10% of patients
who repopulated before 16 weeks.
Higher B-cell numbers can be seen as early as 8 weeks
following rituximab therapy (P=0.002) in those pa-
tients who relapsed early (defined as occurring before
18 months, n=37) compared with patients who relapsed
late (>18 months, or remain in remission, n=24) (Fig. 1C).
B-cell numbers at relapse differ according to
anti-dsDNA antibody levels
B-cell numbers at relapse were lower than the B-cell num-
bers at baseline (P=0.005, Fig. 2A). Two distinct patient
groups were identified based on anti-dsDNA antibody
levels; one with high levels (>100IU/l, n=17) where
relapse occurred with low B-cell numbers and a second
with low or normal levels (<100IU/l, n=20) where relapse
occurred with normal or high B-cell numbers (Fig. 2B).
Thus patients with levels of anti-dsDNA antibodies
>100IU/l relapsed with lower B-cell numbers than pa-
tients with low or normal levels of anti-dsDNA antibodies
(P=0.02). In addition, B-cell numbers at relapse were sig-
nificantly lower than at baseline in patients with high
anti-dsDNA antibodies (P=0.002) but not in patients
with low anti-dsDNA antibody levels. However, patients
with high levels of anti-dsDNA antibody levels at baseline
do not relapse earlier even though they relapse with fewer
B cells. There was no correlation between B-cell numbers
and C3 levels (unpublished data).
We next analysed whether anti-dsDNA antibody levels
modified the association between earlier disease relapse
and a faster rate of repopulation as shown in Fig. 1.
Disease relapse before 18 months (early) was significantly
associated with earlier repopulation in patients with high
FIG.1The rate of B-cell repopulation compared with the time to clinical relapse in patients with SLE following treatment
with rituximab therapy. (A) KaplanMeier curves comparing the time to B-cell repopulation (>0.0110
9 B cells/l) with the
time to clinical relapse following treatment with rituximab therapy (n=61). (B) Comparison of the clinical relapse rates in
patients who repopulate before 16 weeks (n=10), between weeks 16 and 32 (n=22), and after 32 weeks (n=29). Analysis
was carried out using the log rank test. (C) B-cell numbers are shown from baseline to week 52 between patients who
relapse before 18 months (early, n=37) after treatment and patients who relapse (or remain in remission) after 18 months
(late, n=24). Columns indicate the mean B-cell number and bars indicate the S.E.M. Differences between groups were
analysed by the MannWhitney rank-sum test.
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bodies (Fig. 2C). However, repopulation to higher num-
bers of B cells (0.1110
9 B cells/l) did not occur any
more rapidly in patients with high anti-dsDNA antibody
levels in earlier relapsers (Fig. 2D). In contrast, patients
with low or normal anti-dsDNA antibody levels who
relapsed before 18 months attained B-cell numbers
>0.1110
9 B cells/l more rapidly than patients who
relapsed after 18 months with low anti-dsDNA antibody
levels (P=0.01) (Fig. 2D).
The difference in the median time to repopulation
(>0.0110
9 B cells/l) between those patients with high
anti-dsDNA antibody levels who relapsed early and those
who relapsed later or remained in remission was 13 weeks
(25 weeks in the early relapse group, 38 weeks in the late
relapse/remained in remission group). Conversely, in
patients with low levels of anti-dsDNA antibodies, early
relapse was not associated with more rapid repopulation
to >0.0110
9 B cells/l. However, this latter group at-
tained higher B-cell numbers (>0.1110
9 B cells/l) earlier
than patients who relapsed late or remained in remission.
The difference in the median time to repopulation to
this higher B-cell level between early and late relapse/
remained in remission in patients with low anti-dsDNA
levels was >58 weeks [48 weeks (early) compared with
>104 weeks (late)].
A decrease in anti-dsDNA antibody levels was
associated with remission in patients with
high levels at baseline
To determine whether changes in anti-dsDNA antibody
levels correlated with clinical relapse following rituximab
FIG.2B-cell numbers in rituximab-treated patients who relapse with high anti-dsDNA antibody levels compared with
those that relapse with low anti-dsDNA antibody levels. (A) B-cell numbers at baseline and clinical relapse (n=37).
(B) B-cell numbers at baseline and relapse divided according to high (>100IU/l, n=17) and low (n=20) anti-dsDNA
antibody levels measured at relapse. (C) KaplanMeier curves comparing time to B-cell repopulation >0.0110
9 B cells/l
and (D) >0.1110
9 B cells/l in patients with high or low levels of anti-dsDNA antibodies at baseline who relapse either
before or after 18 months. Comparisons of the curves were carried out using the log rank test. NS=P>0.05.
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four time points: baseline, B-cell depletion, B-cell repopu-
lation and relapse/remission (Fig. 3A). Remission was
defined as no relapse within 12 months of repopulation.
In patients with high levels of anti-dsDNA antibodies who
remain in remission (n=9), there was a significant
decrease in levels of anti-dsDNA antibodies between
baseline and repopulation (P<0.01). Despite this
decrease, anti-dsDNA antibody levels remained signifi-
cantly higher in these patients compared with those who
had low or normal levels at baseline (P<0.01). Levels of
anti-dsDNA antibodies did not fall at any time point in
patients with high levels at baseline who relapsed
(n=17), rather there was a significant increase in anti-
dsDNA antibody levels associated with relapse
(P<0.05). Overall, there was a larger percentage
decrease in the levels of anti-dsDNA antibodies in those
patients who remain in remission and who had baseline
levels >100IU/l compared with those who relapsed
(Fig. 3B). Correlating the decrease in anti-dsDNA antibody
levels with the duration of B-cell depletion indicates that
there was a greater decline in anti-dsDNA antibody levels
the longer B cells remained<0.0110
9 B cells/l (R=0.42,
P=0.003) (Fig. 3C).
Different B-cell phenotypes correlate with disease
relapse
Given that patients with high anti-dsDNA antibody levels
relapsed with lower B-cell numbers than patients with low
anti-dsDNA antibody levels, we hypothesized that there
might be differences in B-cell subsets according to
anti-DNA levels in patients during relapse and remission.
In a subset of patients (n=32), we analysed the different
B-cell subsets in relapsing patients and those who re-
mained in remission. As shown in Fig. 4, patients who
had high anti-dsDNA antibodies at relapse (n=6) also
had increased percentages of IgD
CD27
hi plasmablasts
(P<0.01) compared with patients who remained in remis-
sion (n=9). In contrast, patients who had low or normal
levels of anti-dsDNA antibodies had an increased
FIG.3Changes in anti-dsDNA antibody levels following rituximab therapy in relapsing patients compared with those that
remain in remission. (A) Anti-dsDNA antibody levels are shown at baseline, during B-cell depletion, at B-cell repopulation
and at remission or clinical relapse in patients who had either high levels [>100IU/l, n=9 (remission), n=17 (relapse)]
or low levels [n=15 (remission), n=20 (relapse)] at baseline. Columns indicate the mean; bars indicate the S.E.M.( B)
Percentage change in anti-dsDNA antibody levels after rituximab therapy in patients with high levels at baseline that
go into remission or relapse after B cells repopulate. Lines inside the boxes indicate the median; outer borders of the
boxes indicate the 25th and 75th percentiles; bars extending from the boxes indicate the range. Differences between
the groups were analysed by the MannWhitney rank-sum test. (C) Correlation between the change in anti-dsDNA
antibody levels prior to B-cell repopulation and the time to B-cell repopulation.
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CD27
 (double negative) memory B
cells at relapse (n=10) compared with patients who did
not experience a disease flare (n=7)(P=0.01).
Discussion
Our results indicate that patients with SLE respond
differently to BCDT depending on the duration of B-cell
depletion, their levels of anti-dsDNA antibodies and the
type of B cells that repopulate. Two distinct groups of
patients could be defined according to whether they
relapsed with high levels of anti-dsDNA antibodies
(>100IU/l) or with normal or slightly raised levels. Most
striking were the very low B-cell numbers at which
patients with high anti-dsDNA antibody levels relapsed.
These numbers were far below the numbers seen during
the flare in disease that prompted the initial rituximab
therapy, whereas patients with low anti-dsDNA
antibody levels relapsed with similar numbers of B cells
found before rituximab therapy. Moreover, patients
with high levels of anti-dsDNA antibodies relapse later if
their B cells remain <0.0110
9 B cells/l for a longer
period. Once this low threshold was attained, further
increases in B-cell numbers did not distinguish early and
late relapsers in patients with high anti-dsDNA antibody
levels. These observations could reflect the kinetics of
plasma cell repopulation, which was associated with
relapse in patients with high anti-dsDNA antibody levels.
It is tempting to speculate that fewer plasma cells are
required to induce a relapse compared with IgD
CD27

double-negative B cells found in patients with normal or
low anti-dsDNA antibody levels, where disease flare was
associated with higher B-cell numbers. Thus plasma cells,
via the production of anti-dsDNA antibodies, may be more
potent inducers of lupus disease than other B-cell
subsets.
FIG.4B-cell subsets at clinical relapse in patients divided according to anti-dsDNA antibody levels. Peripheral blood
B cells (gated on CD19) were analysed by flow cytometry for the expression of IgD and CD27. Representative and
cumulative data are shown. Percentages of plasmablasts (IgD
CD27
hi) or double-negative memory B cells (IgD
CD27
)
in age- and sex-matched healthy controls (n=19) and in patients who are in remission or relapse with high [>100IU/l,
n=9 (remission), n=6 (relapse)] or low anti-dsDNA antibody levels (n=7, remission, n=10, relapse) are indicated.
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hi plasmablasts show
a strong correlation with anti-dsDNA levels [15], increased
IgD
CD27
 B cells, though associated with SLE [16], are
not consistently correlated with anti-dsDNA antibody
levels [17]. It has been suggested that IgD
CD27

B cells arise through a non-germinal centre pathway,
though their provenance has yet to be proved. The ab-
sence of CD27, which binds to CD70 on activated T cells,
could impair the ability of these double-negative B cells to
respond to T-cell help and differentiate into plasma cells
[18]. Experimental models of SLE have suggested that
B cells may also contribute to pathogenesis through anti-
body-independent mechanisms, perhaps by driving T-cell
autoimmunity [19, 20]. Since there was no association
between plasma cells and disease flare in patients with
normal or minimally raised anti-dsDNA antibody levels, it
is possible that IgD
CD27
 memory B cells contribute
to the pathogenesis of lupus through an antibody-
independent mechanism.
SLE has long been associated with B-cell lymphopenia
[21, 22], although the underlying mechanisms remain
unclear. Although we have interpreted our data that
relapse occurs at low B-cell numbers in patients with
high anti-dsDNA antibody levels as indicating that plas-
mablasts are potent inducers of disease, it also possible
that these antibodies are directly reducing B-cell num-
bers, perhaps by inducing apoptosis [23]. Lymphopenia
has long been ascribed to the presence of autoantibodies
[24], and there is an association between anti-dsDNA anti-
bodies and lymphopenia [25, 26]. One cytokine with the
ability to reverse the B-cell lymphopenia in lupus is B-cell
activating factor (BAFF), due to its potent ability to main-
tain B-cell survival, and it is increased in the serum of
lupus patients. One report suggested an association
between BAFF and high anti-dsDNA antibody levels [27],
though this has not been confirmed by others [28, 29].
Although BAFF levels also increase following rituximab
therapy, it has not been associated with duration of de-
pletion or disease flare [28]. Strategies that could target
both BAFF and rituximab may aid in maintaining low B-cell
numbers and preventing disease relapse.
Several different regimens of anti-CD20 therapy have
been used in BCDT but the most effective has yet to be
established. The results from this study suggest that the
optimum treatment regimen could depend upon the base-
line levels of anti-dsDNA antibodies. In patients with
high anti-dsDNA antibody levels where relapse occurred
at lower B-cell levels, a tailored treatment regimen is
required to ensure their B-cell numbers remain low.
In addition, the longer these patients remain depleted of
B cells, the more likely anti-dsDNA antibody levels will fall.
The optimum duration of depletion still needs to be estab-
lished, but is likely to vary between patients. Patients with
low levels of anti-dsDNA antibodies tend to flare at higher
B-cell numbers, and therefore the target for depletion
does not need to be as stringent as patients with
high anti-dsDNA antibody levels. Future therapeutic stra-
tegies might also target specific B-cell subsets: CD27
hi
plasmablasts in patients with high levels of anti-dsDNA
antibodies, but IgD
CD27
 memory B cells in patients
with low levels. In conclusion, this study suggests that in
therapeutic trials consideration needs to be given to the
heterogeneous nature of the disease and the different
mechanisms by which B-cell targeted therapy could
induce remission.
Rheumatology key messages
. Low B-cell numbers at relapse after rituximab in
lupus patients is associated with high anti-dsDNA
antibody levels.
. Plasmablasts dominated repopulating B-cells only
in lupus patients with high anti-dsDNA antibody
levels.
. Anti-dsDNA antibody levels fell only in those
rituximab-treated patients who did not relapse.
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